Processa Pharmaceuticals (PCSA) Restructuring Costs (2025 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Restructuring Costs came in at $585743.0 in Q2 2026, down 6.78% on a YoY basis from $628330.0 in Q2 2025, and down 13.4% quarter-over-quarter from $676382.0 in Q1 2026.
Powered by 
Analysis
Processa Pharmaceuticals (PCSA) Restructuring Costs (2025 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has reported Restructuring Costs for 2 consecutive years, with $585743.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Restructuring Costs fell 6.78% year-over-year to $585743.0; the trailing twelve-month figure through Jun 2026 stood at $2.6 million (changed N/A YoY), and the FY2025 full-year result was $2.8 million, up 40.62% from the prior year.
- Restructuring Costs declined to $585743.0 in Q2 2026 per PCSA's latest filing, from $676382.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $676382.0 in Q1 2026 and bottomed at $585743.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
| 10 | Processa Pharmaceuticals | 5.75 Mn | 5.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 585,743.00 |
| Mar 31, 2026 | 676,382.00 |
| Jun 30, 2025 | 628,330.00 |
| Mar 31, 2025 | 673,779.00 |